These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 22475690)

  • 1. [Consensus on the clinical impact of the new scientific evidence available on benign prostatic hyperplasia].
    Cózar-Olmo JM; Hernández-Fenández C; Miñana-López B; Amón-Sesmero JH; Montlleó-González M; Rodríguez-Antolín A; Caballero-Martínez F
    Actas Urol Esp; 2012 May; 36(5):265-75. PubMed ID: 22475690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Latest trends and recommendations on epidemiology, diagnosis, and treatment of benign prostatic hyperplasia (BPH)].
    Gabuev A; Oelke M
    Aktuelle Urol; 2011 May; 42(3):167-78. PubMed ID: 21604233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia.
    Shore N
    Expert Opin Investig Drugs; 2010 Feb; 19(2):305-10. PubMed ID: 20050813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
    Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The natural history of benign prostatic hyperplasia.
    Fitzpatrick JM
    BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can simple tests performed in the primary care setting provide accurate and efficient diagnosis of benign prostatic hyperplasia? Rationale and design of the Diagnosis Improvement in Primary Care Trial.
    Carballido J; Fourcade R; Pagliarulo A; Cricelli C; Brenes F; Pedromingo-Marino A; Castro R
    Int J Clin Pract; 2009 Aug; 63(8):1192-7. PubMed ID: 19558487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
    Roehrborn CG
    BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry.
    Wei JT; Miner MM; Steers WD; Rosen RC; Seftel AD; Pasta DJ; Carman WJ; Roehrborn CG;
    J Urol; 2011 Sep; 186(3):971-6. PubMed ID: 21791352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
    Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
    BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997.
    Sarma AV; Jacobson DJ; McGree ME; Roberts RO; Lieber MM; Jacobsen SJ
    J Urol; 2005 Jun; 173(6):2048-53. PubMed ID: 15879823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
    Miner M; Rosenberg MT; Perelman MA
    Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bloodless management of benign prostatic hyperplasia: medical and minimally invasive treatment options.
    Liatsikos E; Kyriazis I; Kallidonis P; Stolzenburg JU
    Aging Male; 2011 Sep; 14(3):141-9. PubMed ID: 21247241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression.
    Trachtenberg J
    BJU Int; 2005 Jun; 95 Suppl 4():6-11. PubMed ID: 15871730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
    Emberton M; Zinner N; Michel MC; Gittelman M; Chung MK; Madersbacher S
    BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG
    BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canadian guidelines for the management of benign prostatic hyperplasia.
    Nickel JC; Herschorn S; Corcos J; Donnelly B; Drover D; Elhilali M; Goldenberg L; Grantmyre J; Laroche B; Norman R; Piercy B; Psooy K; Steinhoff G; Trachtenberg J; Saad F; Tanguay S; ;
    Can J Urol; 2005 Jun; 12(3):2677-83. PubMed ID: 16011814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Definition of at-risk patients: dynamic variables.
    Emberton M
    BJU Int; 2006 Apr; 97 Suppl 2():12-5; discussion 21-2. PubMed ID: 16507047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Benign prostatic hyperplasia and evidence based medicine: its approach in clinical practice].
    Carballido Rodríguez JA; Rodríguez Vallejo JM; del Llano Señaris JE
    Med Clin (Barc); 2000; 114 Suppl 2():96-104. PubMed ID: 10916816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.